You are here

Bayer

Bayer's Nubeqa one step closer to blockbuster status thanks to FDA priority review in potential new use

Fierce Pharma

Tue, 05/3/22 - 10:48 pm

prostate cancer

Bayer nabs yet another oncology leader from GSK to bolster cancer efforts

Fierce Biotech

Fri, 04/22/22 - 10:34 am

First-quarter biotech risers work hard for the win

EP Vantage

Thu, 04/21/22 - 10:32 am

Lantheus Medical

ACC: Bayer’s Kerendia cuts cardio and kidney complications in high-risk patients

Fierce Pharma

Mon, 04/4/22 - 11:20 pm

Running behind Bristol Myers and J&J, Bayer inches forward in the next-gen blood thinner race

Endpoints

Mon, 04/4/22 - 10:56 am

clinical trials

Bristol Myers Squibb

Bayer reloads Leaps with €1.3 billion to step up investments in biotech innovation

MedCity News

Mon, 04/4/22 - 10:19 am

artificial intelligence

A Bayer partner slims down, trimming R&D and enacting layoffs, to better focus on the pair's prostate cancer work

Endpoints

Thu, 03/24/22 - 10:53 am

prostate cancer

Bayer-backed Affini-T snags $175M to enter increasingly crowded KRAS-cancer field

Fierce Biotech

Tue, 03/22/22 - 10:09 am

Affini-T Therapeutics

venture capital

Steep drop in medical device reports on Bayer's Essure in 2021, FDA data show

Medtech Dive

Wed, 03/16/22 - 10:28 am

Amid inflation spike, execs at J&J, Bayer, GSK and more talk higher costs—and what it means for profits

Fierce Pharma

Fri, 03/11/22 - 11:06 am

With Bayer's new launches in infancy, Eylea and Xarelto still rule its pharma business—but for how long?

Fierce Pharma

Tue, 03/1/22 - 10:04 pm

Kodiak's Eylea rival hits 'major disappointment' with failure in first of 6 phase 3 studies

Fierce Biotech

Wed, 02/23/22 - 09:28 pm

Kodiak Sciences

Bayer hikes Nubeqa's peak sales to more than €3B on prostate cancer data, teeing up new 3-way battle against Pfizer-Astellas, J&J

Fierce Pharma

Fri, 02/18/22 - 10:35 am

prostate cancer

Latest data on Bayer's Essure show more patients had device removed: FDA

Medtech Dive

Tue, 02/15/22 - 10:43 am

Bayer-owned AskBio will shift focus toward its doggybone DNA in restructure with Touchlight

Endpoints

Wed, 02/9/22 - 10:47 pm

Bayer-led project on AI in trials eyes ‘virtual’ placebo groups

Pharmaforum

Fri, 02/4/22 - 12:53 pm

artificial intelligence

clinical trials

Bayer Discontinues Clinical Development Candidate Eliapixant (BAY1817080), Evotec Regains the Rights to all P2X3 Assets

BioSpace

Fri, 02/4/22 - 11:09 am

Roche grabs FDA okay for would-be blockbuster eye drug faricimab

Pharmaforum

Mon, 01/31/22 - 10:51 am

Backed by Bayer's Leaps, Boston-based Cellino lands $80M for cell therapy-in-box

Endpoints

Tue, 01/25/22 - 10:48 am

regenerative medicine

Bayer jumps on board Mammoth's ultra-small CRISPR tech with sights set first on liver disease

Endpoints

Mon, 01/10/22 - 11:28 am

Jennifer Doudna

Mammoth Biosciences

Pages